Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy
NCT03548571
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Glioblastoma
Interventions
BIOLOGICAL:
Dendritic cell immunization
DRUG:
Adjuvant temozolomide
Sponsor
Oslo University Hospital